AstraZeneca, a UK-based pharmaceutical company, and MedImmune, its global biologics research and development arm, announced on Friday that the US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukaemia
(HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
The data regarding the influence of analogues of purine nucleosides on reproduction functions results undoubtedly from the epidemiology of hairy cell leukaemia
The 40-year-old has been diagnosed with hairy cell leukaemia
- a chronic blood cancer for which there is currently no cure.
Ferdie Stern passed away peacefully in Durban on 1 June 2010 in his 91st year, a victim of hairy cell leukaemia
. His parents, Simon and Bertha, had emigrated from a small village, Rohatten, in Austria and settled in Dordrecht in the Eastern Cape where they farmed.
Jim was first diagnosed with the rare blood cancer, hairy cell leukaemia
, in 2004.
Chronic Lymphoid leukaemia and hairy cell leukaemia
due to chronic exposure to benzene: report of three cases.
Innate is licensing the US and EU commercial rights to recently FDA-approved Lumoxiti (moxetumomab pasudotox) for hairy cell leukaemia
M2 EQUITYBITES-September 17, 2018-AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
M2 PHARMA-September 17, 2018-AstraZeneca announces US FDA approval of Lumoxiti to treat hairy cell leukaemia
The differential diagnoses of PCL include B-cell chronic lymphocytic leukaemia, hairy cell leukaemia
and marginal zone lymphomas with circulating lymphocytes.
Simple diagnostic assay for hairy cell leukaemia
by immunocytochemical detection of annexin A1 (ANXA1).
Around 21,500 people get leukaemia in the UK every year but fewer than 100 get the hairy cell leukaemia
which attacked his body.